Cargando…

Nanomedicine targets iron metabolism for cancer therapy

Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolism...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Liangru, Chen, Hanqing, Zhao, Ruifang, Zhu, Motao, Nie, Guangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898713/
https://www.ncbi.nlm.nih.gov/pubmed/34962017
http://dx.doi.org/10.1111/cas.15250
_version_ 1784663718420807680
author Lin, Liangru
Chen, Hanqing
Zhao, Ruifang
Zhu, Motao
Nie, Guangjun
author_facet Lin, Liangru
Chen, Hanqing
Zhao, Ruifang
Zhu, Motao
Nie, Guangjun
author_sort Lin, Liangru
collection PubMed
description Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) Abs, and cytotoxic ligands conjugated to transferrin, has become a considerable strategy for cancer therapy. However, there remain major limitations for potential translation to the clinic based on the regulation of iron metabolism in cancer treatment. Nanotechnology has made great advances for cancer treatment by improving the therapeutic potential and lowering the side‐effects of the proved drugs and those under various stages of development. Early studies that combined nanotechnology with therapeutic means for the regulation of iron metabolism have shown certain promise for developing specific treatment options based on the intervention of cancer iron acquisition, transportation, and utilization. In this review, we summarize the current understanding of iron metabolism involved in cancer and review the recent advances in iron‐regulatory nanotherapeutics for improved cancer therapy. We also envision the future development of nanotherapeutics for improved treatment for certain types of cancers.
format Online
Article
Text
id pubmed-8898713
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88987132022-03-11 Nanomedicine targets iron metabolism for cancer therapy Lin, Liangru Chen, Hanqing Zhao, Ruifang Zhu, Motao Nie, Guangjun Cancer Sci Review Articles Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) Abs, and cytotoxic ligands conjugated to transferrin, has become a considerable strategy for cancer therapy. However, there remain major limitations for potential translation to the clinic based on the regulation of iron metabolism in cancer treatment. Nanotechnology has made great advances for cancer treatment by improving the therapeutic potential and lowering the side‐effects of the proved drugs and those under various stages of development. Early studies that combined nanotechnology with therapeutic means for the regulation of iron metabolism have shown certain promise for developing specific treatment options based on the intervention of cancer iron acquisition, transportation, and utilization. In this review, we summarize the current understanding of iron metabolism involved in cancer and review the recent advances in iron‐regulatory nanotherapeutics for improved cancer therapy. We also envision the future development of nanotherapeutics for improved treatment for certain types of cancers. John Wiley and Sons Inc. 2022-02-07 2022-03 /pmc/articles/PMC8898713/ /pubmed/34962017 http://dx.doi.org/10.1111/cas.15250 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Lin, Liangru
Chen, Hanqing
Zhao, Ruifang
Zhu, Motao
Nie, Guangjun
Nanomedicine targets iron metabolism for cancer therapy
title Nanomedicine targets iron metabolism for cancer therapy
title_full Nanomedicine targets iron metabolism for cancer therapy
title_fullStr Nanomedicine targets iron metabolism for cancer therapy
title_full_unstemmed Nanomedicine targets iron metabolism for cancer therapy
title_short Nanomedicine targets iron metabolism for cancer therapy
title_sort nanomedicine targets iron metabolism for cancer therapy
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898713/
https://www.ncbi.nlm.nih.gov/pubmed/34962017
http://dx.doi.org/10.1111/cas.15250
work_keys_str_mv AT linliangru nanomedicinetargetsironmetabolismforcancertherapy
AT chenhanqing nanomedicinetargetsironmetabolismforcancertherapy
AT zhaoruifang nanomedicinetargetsironmetabolismforcancertherapy
AT zhumotao nanomedicinetargetsironmetabolismforcancertherapy
AT nieguangjun nanomedicinetargetsironmetabolismforcancertherapy